For its two lead oncology programs, the company will pursue “market-based pricing”, moving away from plans to “dramatically lower prices” for treatments.
The issue of pricing is a familiar discussion for the pharma industry and Ruchin Kansal, of Virtusa, believes that there is the potential for a win-win situation.